BEAT AML®
MASTER CLINICAL TRIAL
A groundbreaking collaborative clinical trial targeting acute myeloid leukemia
What is the Beat AML® Master Clinical Trial?

The Leukemia & Lymphoma Society (LLS) is leading the Beat AML Master Clinical Trial, a groundbreaking collaborative clinical trial testing several novel targeted therapies for patients with acute myeloid leukemia (AML). AML is one of the deadliest blood cancers and the most commonly diagnosed form of leukemia in adults.

In the past two years alone, after four decades with almost no advances in AML treatment, the U.S. Food & Drug Administration (FDA) approved multiple new AML therapies—all advanced with LLS support. Today, we know that AML is not a single disease, but rather a group of more than 10 subtypes and other rare mutations. With advancements in genomics and precision medicine, we can now identify and target specific types of AML. This is fueling a renaissance in AML research and discovery.

With advancements in genomics and precision medicine, we can now identify and target specific types of AML. This is fueling a renaissance in AML research and discovery.

Why is this study being done?

Each year, more than 20,000 Americans are diagnosed with AML, one of the most lethal blood cancers. While therapies for other blood cancers have made remarkable leaps forward, until recently, the standard of care for AML—a combination of toxic chemotherapies—had changed very little over the past four decades.

Even with recent progress, much work remains. Only about one in four AML patients survives five years after diagnosis. LLS is leading the charge against AML through this collaborative clinical trial that aims to change the paradigm of treatment through a precision medicine approach.

Who is involved?

LLS is leading the Beat AML Master Clinical Trial, the first collaborative clinical trial in blood cancer. The trial is open at multiple top cancer centers across the country, where several investigational targeted therapies are being tested.

The FDA granted LLS permission to run the trial and worked closely with LLS to develop the trial protocol. Three world-renowned blood cancer scientists lead the clinical trial: Brian Druker, MD, The Knight Cancer Institute at Oregon Health & Science University; John Byrd, MD, The Ohio State University Comprehensive Cancer Center; and Ross Levine, MD, Memorial Sloan Kettering Cancer Center.

Additionally, multiple pharmaceutical companies, prominent scientists at top cancer centers, several technology companies and the FDA join us in a shared commitment to bring the promise of precision medicine to AML patients.
THE BEAT AML LEAD INVESTIGATORS

Brian Druker, MD,
The Knight Cancer Institute at Oregon Health & Science University

John Byrd, MD,
The Ohio State University Comprehensive Cancer Center

Ross Levine, MD,
Memorial Sloan Kettering Cancer Center
Why is LLS convening the Beat AML® Master Clinical Trial?

As the voice for blood cancer patients, LLS is uniquely qualified to lead this unprecedented clinical trial collaboration. This is because LLS is:

**Patient-focused:** LLS exists to find cures and ensure that patients have access to the best available treatments.

**A Trusted Convener:** LLS serves as a catalyst for collaboration among clinicians, researchers, companies and regulators.

**A Leader in AML:** LLS has unparalleled expertise and dedicates a quarter of our research funds to AML every year.

As the voice for blood cancer patients, LLS is uniquely qualified to lead this unprecedented clinical trial collaboration.

Findings will help inform future clinical trials and treatment options for AML, and the unique collaborative approach of the Beat AML Master Clinical Trial will stand as a model for future cancer clinical trials.

**HOW MANY PATIENTS WILL TAKE PART IN THE BEAT AML MASTER CLINICAL TRIAL?**

LLS expects up to 1,000 patients to enroll in the trial.

**WHERE CAN I LEARN MORE ABOUT THE BEAT AML MASTER CLINICAL TRIAL?**

For detailed information, go to our website: [www.LLS.org/beataml](http://www.LLS.org/beataml)